Market OverviewThe HER2 negative breast cancer market is expanding as hormone receptor positive advances. HR+ HER2- is the most common subtype. The market is projected to grow through 2030, driven by CDK4/6 inhibitors, endocrine therapy, and genomic profiling. Growing adoption of the HER2 Negative Breast Cancer Market reflects the expanding recognition that CDK4/6 inhibitors improve survival....
Bangla